Julie Green Sells 18,425 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Julie Green sold 18,425 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $0.84, for a total transaction of $15,477.00. Following the transaction, the insider directly owned 168,937 shares in the company, valued at $141,907.08. This trade represents a 9.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Julie Green also recently made the following trade(s):

• On Monday, August 17th, Julie Green sold 22,355 shares of Invivyd stock. The stock was sold at an average price of $0.72, for a total value of $16,095.60.

Invivyd Price Performance

Shares of IVVD stock opened at $0.96 on Thursday. The stock’s fifty day simple moving average is $0.77 and its 200 day simple moving average is $1.23. The firm has a market cap of $282.82 million, a price-to-earnings ratio of -2.91 and a beta of 0.71. Invivyd, Inc. has a one year low of $0.48 and a one year high of $3.07.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The company had revenue of $14.29 million for the quarter, compared to analyst estimates of $14.40 million. On average, research analysts anticipate that Invivyd, Inc. will post -0.52 earnings per share for the current year.

Key Invivyd News

Here are the key news stories impacting Invivyd this week:

• Positive Sentiment: Several research firms maintain Buy ratings on Invivyd, and the stock’s average analyst price target remains substantially above its current trading range. Institutional ownership is also significant, with investors holding about 70% of the outstanding shares. MarketBeat Invivyd analyst and institutional data
• Neutral Sentiment: Robert Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold Invivyd shares on August 17 or 18 at approximately $0.72 or $0.84. The transactions reduced their individual holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings indicate that the sales were made to cover tax-withholding obligations associated with vested equity awards. That makes them less bearish than discretionary open-market sales intended to reduce exposure.
• Negative Sentiment: The unusually broad participation by multiple insiders could still create a short-term sentiment overhang, particularly for Invivyd’s relatively small market capitalization. Investors also continue to face fundamental risks: the company recently missed quarterly earnings expectations, reported a net loss, and remains dependent on the development and commercialization of its antibody-based infectious-disease pipeline.

Wall Street Analysts Forecast Growth

IVVD has been the subject of a number of recent analyst reports. BTIG Research reiterated a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Wall Street Zen lowered shares of Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a research note on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $8.00.

Institutional Trading of Invivyd

Several large investors have recently made changes to their positions in IVVD. Jupiter Topco LLC acquired a new stake in shares of Invivyd in the second quarter valued at $30,048,000. Perceptive Advisors LLC acquired a new position in Invivyd during the 4th quarter worth about $53,809,000. BVF Inc. IL bought a new stake in Invivyd during the 4th quarter worth about $48,227,000. RA Capital Management L.P. bought a new stake in Invivyd during the 3rd quarter worth about $18,831,000. Finally, BlackRock Inc. acquired a new stake in Invivyd in the 2nd quarter valued at about $14,076,000. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.